DEGS1: A Potential Drug Target for Cancer (G8560)

Target Name: DEGS1

NCBI ID: G8560

DEGS1

DEGS1: A Potential Drug Target for Cancer

DEGS1 (DEGS1 variant 2) is a gene that encodes a protein known as DEGS1. DEGS1 is a non-coding RNA molecule that is expressed in various tissues and cells throughout the body. It is a key regulator of gene expression and has been implicated in a number of cellular processes, including cell growth, differentiation, and survival.

One of the unique features of DEGS1 is its ability to interact with other proteins, particularly with the protein known as p53. p53 is a well-known tumor suppressor protein that is often mutated in cancer and can lead to the development of cancer. DEGS1 has been shown to physically interact with p53 and can modulate its activity.

This interaction between DEGS1 and p53 has led to the hypothesis that DEGS1 may be a drug target or biomarker for cancer. In fact, studies have shown that inhibiting DEGS1 can lead to a reduction in the growth and survival of cancer cells. This suggests that DEGS1 may be a useful target for cancer treatment.

In addition to its potential as a drug target, DEGS1 has also been shown to be a potential biomarker for cancer. The expression of DEGS1 has been shown to be elevated in a variety of cancer types, including breast, ovarian, and colorectal cancers. This suggests that DEGS1 may be a useful biomarker for these cancers and could be used for the development of targeted therapies.

Another potential application of DEGS1 is its role in cell signaling. DEGS1 has been shown to play a role in regulating cellular signaling pathways, including the TGF-β pathway. This pathway is involved in a variety of cellular processes, including cell growth, differentiation, and survival. By modulating the activity of TGF-β, DEGS1 has been shown to influence the growth and survival of various cell types.

In conclusion, DEGS1 is a gene that has been shown to interact with p53 and has been implicated in a number of cellular processes. Its potential as a drug target or biomarker for cancer makes it an attractive target for researchers to explore further. Further studies are needed to fully understand the role of DEGS1 in cell signaling and its potential as a drug or biomarker for cancer.

Protein Name: Delta 4-desaturase, Sphingolipid 1

Functions: Has sphingolipid-delta-4-desaturase activity. Converts D-erythro-sphinganine to D-erythro-sphingosine (E-sphing-4-enine) (PubMed:11937514, PubMed:30620337, PubMed:30620338). Catalyzes the equilibrium isomerization of retinols (By similarity)

The "DEGS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEGS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets